Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. - Wikidata - awgldk - TriplyDB

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

http://www.wikidata.org/entity/Q33747987

about

Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation Imaging frontotemporal lobar degeneration.The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Future Directions in Imaging Neurodegeneration.Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults.The overlap between vascular disease and Alzheimer's disease--lessons from pathology.Clinical and imaging features of mixed Alzheimer and vascular pathologies.Amyloid imaging for dementia in clinical practice.Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.Post-mortem assessment in vascular dementia: advances and aspirations.Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.Integrated (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging ((18)F-FDG PET/MRI), a multimodality approach for comprehensive evaluation of dementia patients: A pictorial essay.Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model.Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Biomarkers in Neurodegenerative Diseases.FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.Quantification of 18F-florbetapir PET: comparison of two analysis methods.The emerging role of PET imaging in dementia.Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease.Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.Biomathematical screening of amyloid radiotracers with clinical usefulness index.Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.Spatiotemporal distribution of β-amyloid in Alzheimer's disease results from heterogeneous regional carrying capacities.Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds.Establishing Amyloid PET Imaging Biomarkers: Ongoing Efforts.Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes.

P2860

Q26770766-D79EAE87-6AED-4CAD-AEFF-95E1ED838E9C Q26801654-43BF107C-AC30-418B-8DAA-587C25731B4B Q27303745-49374FE9-19A2-4A00-A1A7-9ED5C0DC3A88 Q30846573-8A85BEB4-EC13-44F3-9197-F07F57F6437D Q31147579-85DA213F-19D4-48E5-BC9C-016B3793BA6D Q31162702-75A49D32-D11C-45F7-816A-EFF43EFE9DFE Q33775095-DBEBBCC0-51D9-435A-A5B1-6F70922C6504 Q34484708-DE70FF3D-50A2-4E07-9AA8-D316DA3228F6 Q35125123-AD52FD59-B435-4196-92F8-35F1D30EBB9F Q35690134-A871EC13-788D-4137-A3E7-29D30A0F1A8F Q35896890-5F6DC2D2-A3FC-4EB4-B68A-F53A016612FD Q36018654-244FD164-0826-4CB5-A60F-9597DC50E5F9 Q36124590-AC22A45B-2C5E-4F00-8FA7-DAB15A261EC9 Q36267484-E410723E-25D8-4DAC-8E36-CE1F5A7415BE Q36409826-3CB701FF-ABFB-4B4B-8183-92FEB324639C Q36627314-9F6F3AF9-42A7-4ADA-8724-8500ABCDCCCF Q36796489-C59A9CF4-9E98-4858-9FC6-6B62FABB37CE Q37530392-502EAB08-6768-4E93-921C-FB71AE160271 Q37647518-DF2E4FB5-2E08-412F-8A18-464D4B696F59 Q37727300-A1A3BC85-87A4-4A18-AF96-AEB82D84CD1F Q38600277-48618E28-B8E9-4372-AEFA-0E35A42A938E Q38712820-68DF8CE8-FC4F-4AF6-882E-808711ED507E Q38979999-D67BD147-0DF5-44BB-96CB-E74472860FE7 Q39413097-26CFD5F2-C98A-4D6C-BE28-45236D426945 Q39775642-1B069E74-3872-43A8-AF6B-47E6D884D537 Q40135278-A3639634-1535-448D-BB6E-34DBECC1BA2A Q40600414-DF197EBB-6EE4-4747-8390-4171A7D5CFAE Q41477369-C3851856-B4FD-4873-B339-C692B729FD45 Q42701971-F7254783-7100-4E3A-A2F9-DA2EFBB380E5 Q46254853-2067BEA4-12E9-4628-9EB8-50C8EDF2F80B Q46427093-14FD8096-80F3-4431-990F-F077C13C4673 Q47110677-2CDDFB91-A5EB-4681-A92C-C468D1CB5D7E Q47198229-0954E176-1405-4468-906D-206F8D0C2C57 Q47200597-39FDD40E-D781-433E-92A2-E1AFBCC6ECBF Q47241835-28358F1D-A265-4FED-8075-BE458E1D37EA Q47288867-9D8C19BA-1A82-4BD8-BE12-EAE49CEEA480 Q47394170-B185336B-835E-45F4-B79C-9232050859C0 Q47926987-5FF0DF86-11CD-4311-9413-F80972D1C3A2 Q48165240-EA05E9D1-F1B2-49AA-A7D3-2B7D1234E982 Q48236912-8EE872FE-DAC7-4B3F-8790-F4890CD61880

P2860

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

http://www.wikidata.org/entity/Q33747987

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@ast

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@en

type

label

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@ast

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@en

prefLabel

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@ast

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@en

P1433

Q33747987-75CC09A6-E3EE-4FE4-AD2B-C0302D4768CD

P1476

Q33747987-6AFF7C39-3E44-4F16-BBB3-F2F4BEDA18E4

P2093

Q33747987-20B8B2AB-BD6A-4D62-BEB7-34E97DA2A4E2

Q33747987-60B3F995-70B4-43F7-8495-1C58149F8ED6

Q33747987-89925F0C-AE93-48DC-A10E-F1034514AA21

Q33747987-9A4E1E10-2457-489D-8EB3-9806700D4A32

Q33747987-9FA2090A-24DC-45CE-B1CC-84D07528AA0F

Q33747987-D013CB08-C6E5-498E-BA0B-9839AF656ADD

Q33747987-D102B05C-32BA-423E-BA54-584BC372EC67

Q33747987-D32EE344-7850-45E3-BD9B-F510F092210F

Q33747987-D3CEA031-FE84-4629-8EC3-0D957FD6AFD6

P2860

Q33747987-074F5B8B-9C27-4882-93F2-3A62B4405DD8

Q33747987-1D71C78A-AF4D-42B6-9108-835363D8658A

Q33747987-1F7C0A97-F474-4E64-AD3F-9849FFB2FB5E

Q33747987-1FAB2257-3533-4567-8F76-39B9F43522D4

Q33747987-2632C2AF-D208-463F-AF8A-43C2E1D60191

Q33747987-2ECFFFDB-EAB5-4193-BE97-CD47261917D1

Q33747987-3A5FEF91-A217-46A0-8A6B-8BAAA2BF058E

Q33747987-45146CED-0C07-43D0-ADB6-F86DF183B4B4

Q33747987-5692FA40-BD0F-46D1-BC72-DBB113DBF537

Q33747987-6CC76307-33A1-4B43-8704-ED10617CC49E

P2888

Q33747987-691BF5AC-03DD-4A29-A1C4-38F6D18D6825

P304

Q33747987-C4C483E6-B004-4B78-BE05-3BE4F3B52A93

P31

Q33747987-EA4BACCF-8D25-4F24-9056-CDBAC6B5778E

P356

Q33747987-AC8EB664-7DF3-400D-B1DE-DEABCA3B7D01

P433

Q33747987-335E2F56-8263-4124-94DD-D9043499BAE3

P478

Q33747987-8633ACE1-8809-472B-9BB7-6F73CFC427DD

P50

Q33747987-3F726156-A5A4-4F1A-AE85-89EB01654C04

P577

Q33747987-22B54804-4D3C-4E56-A0EC-B932328876F9

P698

Q33747987-7DBD239E-5D1F-4579-9A2E-8DEB05BC26FA

P921

Q33747987-66911B35-CD18-4230-8002-D984F4FFC7EA

P932

Q33747987-B9307AC3-F2F4-4078-9600-BE19EB2BBCB5

P356

S00259-014-2753-3

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

@en

P2093

B A Thomas

http://www.w3.org/2001/XMLSchema#string

L Thurfjell

http://www.w3.org/2001/XMLSchema#string

M Mintun

http://www.w3.org/2001/XMLSchema#string

M Pontecorvo

http://www.w3.org/2001/XMLSchema#string

M Schmidt

http://www.w3.org/2001/XMLSchema#string

R Margolin

http://www.w3.org/2001/XMLSchema#string

S L Baker

http://www.w3.org/2001/XMLSchema#string

S M Landau

http://www.w3.org/2001/XMLSchema#string

W J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography

Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods

Association of lifetime cognitive engagement and low β-amyloid deposition

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Relationships between biomarkers in aging and dementia.

P2888

s00259-014-2753-3

P304

1398-1407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-014-2753-3

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24647577

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4055504

http://www.w3.org/2001/XMLSchema#string